Production (Stage)
Anavex Life Sciences Corp.
AVXL
$7.53
-$0.14-1.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.69% | 8.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.79% | -3.34% | |||
| Operating Income | 5.79% | 3.34% | |||
| Income Before Tax | 7.56% | -3.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.56% | -4.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.56% | -4.23% | |||
| EBIT | 5.79% | 3.34% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 7.84% | -4.23% | |||
| Normalized Basic EPS | 7.84% | -3.72% | |||
| EPS Diluted | 7.84% | -4.23% | |||
| Normalized Diluted EPS | 7.84% | -3.72% | |||
| Average Basic Shares Outstanding | 0.32% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||